For the fifth consecutive year, L’Institut Servier has supported the annual meeting between Dana-Farber Cancer Institute and Gustave Roussy, a full day of high-level scientific exchange entirely dedicated to innovations in cancer drug research.
Since 2022, the Transatlantic Exchanges in Oncology have brought together the world’s leading oncology researchers each year around a cutting-edge scientific theme. This year, the fifth edition took place at Dana-Farber Cancer Institute in Boston on March 27, 2026, in a hybrid format enabling healthcare professionals and researchers from around the world to follow the sessions in real time.
Jointly organized by Dana-Farber and Gustave Roussy, with the support from L’Institut Servier, the day focused on Transatlantic Innovations in Cancer Drug Research. This edition explored three major scientific fronts: epigenetic therapies, microbiome-driven immunity, and cellular pathway reprogramming, domains that together are shaping a new map of precision oncology.
Epigenetic Therapies: Advances in Precision Oncology
Long confined to fundamental research, epigenetic therapies are now crossing the threshold of clinical translatability. This session explored the latest molecular targets and emerging compounds that are beginning to reshape how precision oncology approaches tumour biology, from chromatin remodelling to DNA methylation.
Microbiome-Driven Immunity: Unlocking Host-Microbe Power
The microbiome is asserting itself as a primary immune actor in oncology, opening therapeutic pathways at the interface of host biology and tumour immunology. This session examined the translational data and mechanistic insights that are turning the gut microbiota from a correlative observation into an actionable target.
Cellular Pathway Reprogramming: New Strategies for Treatment
Where resistance to conventional treatments seems hardest to overcome, modulating intracellular signalling pathways offers new routes forward. This session presented emerging strategies, from targeted degraders to allosteric modulators, that aim to rewire tumour cell behaviour rather than simply block it.
What this day also confirmed is the irreplaceable value of transatlantic collaboration itself. Bringing together translational experts from two complementary scientific ecosystems produces something no single institution can generate alone: collective intelligence that goes further, moves faster, and remains grounded in the reality of patients. This is precisely what L’Institut Servier, Dana-Farber and Gustave Roussy have built over five editions, and what each new meeting reinforces.
Beyond the annual meeting, this tripartite collaboration takes a very concrete form throughout the year: a fellowship program through which L’Institut Servier funds the travel and research stays of scientists from both Gustave Roussy and Dana-Farber Cancer Institute. By enabling this two-way researcher mobility between Paris and Boston, the program ensures that knowledge, methods and connections flow in both directions, strengthening the scientific foundations of the partnership and investing in the people who will shape the future of cancer research.
Stay tuned, interviews about the meeting and an abstract will be available very soon.